Impact of COVID-19 Disease in Early Breast Cancer Management: A Summary of the Current Evidence

Francisco Pimentel Cavalcante, MD; Edson Abdala, MD, PhD; Leonardo Weissmann, MD, MSc; Carlos Eduardo dos Santos Ferreira, MD, PhD; Gilberto Amorim, MD; Vilmar Marques de Oliveira, MD, PhD; Gisah Guilgen, MD; Luciana Landeiro, MD, PhD; João Renato Rebello Pinho, MD, PhD; Alvaro Pulchinelli Jr, MD, PhD; Heber Ribeiro, MD, PhD; Rafael Souza, MD; and Daniela Dornelles Rosa, MD, PhD

abstract

PURPOSE An expert panel on breast cancer and COVID-19 disease was convened to address the impact of the COVID-19 pandemic for early breast cancer (eBC) management.

METHODS To ensure that the most clinically relevant information was addressed, essential information was drawn from several of the latest national and international guidelines and another technical document. The expert panel met in five virtual closed sessions from November 2020 to May 2021 to consult on the relevant data from evidence-based results. The data gathered were discussed on an online platform.

RESULTS This article reports the expert panel’s highlights of these meetings’ discussions. In addition, it provides practical recommendations covering topics regarding diagnosis, treatment, and management of patients with eBC in clinical settings routinely encountered by health care professionals amid the COVID-19 pandemic.

CONCLUSION This article provided guidance on several topics regarding eBC management amid the COVID-19 pandemic to inform safer care practices.

INTRODUCTION

In 2020, the predicted number of new breast cancer (BC) cases was 2.3 million worldwide, with an estimated age-standardized rate incidence of 47.8 per 100,000 person-years and an age-standardized rate mortality of 13.6 per 100,000 person-year with 684,996 deaths predicted. The COVID-19 pandemic has challenged the medical community on many fronts, significantly affecting access to cancer diagnosis and treatment. The fear of becoming infected while using health care facilities, fueled by the rising number of infected individuals seeking medical care, is one of the main factors delaying cancer diagnosis and treatment. A significant decrease in cancer diagnoses has been observed during the COVID-19 pandemic, with the most marked decline seen in BC care (51.8%).

Surgery remains the primary curative treatment for BC. However, because of the COVID-19 pandemic, BC teams have been forced to review triage for surgical procedures to optimize clinical resource usage. This move has entailed assessing risks and deciding which surgery cases should be postponed, such as elective surgeries and taking preventive measures for potentially infected nondeferrable surgery candidates.
**CONTEXT**

**Key Objective**
To discuss relevant evidence-based data on the management of early breast cancer (eBC) during the COVID-19 pandemic.

**Knowledge Generated**
We provided expert panel recommendations regarding the best practices on eBC management during the COVID-19 pandemic, concerning both patient and health care professionals’ health and safety.

**Relevance**
Our results contribute with evidence-based information that supports the development of protocols and algorithms to adapt the management of eBC during the COVID-19 pandemic or during times of higher restrictions.

---

We provided expert panel recommendations regarding the best practices on eBC management during the COVID-19 pandemic.

**RESULTS**

**Clinical Presentation of BC**
BC is a heterogeneous disease with different subtypes. Most patients with BC are asymptomatic (findings from screening mammography), whereas others may present with a palpable lump at diagnosis. eBC (stages I and II) represents more than 75% of cases in most parts of the world. The management of eBC is well-defined according to international protocols. Human epidermal growth factor receptor 2 (HER2)–positive and triple-negative (TN) BC are biologically more aggressive tumors, whereas luminal cancers (which express hormone receptors) are more indolent. On the basis of the Ki-67 proliferation index, the St Gallen Consensus defines two luminal subtypes: luminal A (better prognosis) and luminal B (more aggressive disease). Surgery is the mainstay treatment for eBC, and the procedure may be performed upfront or after neoadjuvant therapy (chemotherapy or endocrine therapy). As a rule, HER2-positive, luminal B, and TN patients are priority categories for urgent BC therapy.

**Pathophysiology**
Patients with cancer have dysregulated immunity with depleted immune cells, such as CD8+ T cells, CD4+ T cells, natural killer cells, and others. COVID-19 disease in patients with cancer significantly increases inflammatory factors and cytokines (high-sensitivity C-reactive protein, procalcitonin, interleukin [IL]-2, IL-6, and IL-8), possibly explaining the poorer prognosis in individuals with cancer relative to those without cancer. SARS-CoV-2 infection can enter the cell by mediating spike proteins using the angiotensin-converting enzyme 2 receptor via plasma membrane fusion or endosomes. SARS-CoV-2 infection stimulates the innate immune system and antigen-specific responses of B and T cells through a mechanism similar to that seen for the influenza virus. The development of virus-neutralizing antibodies is essential for protection against viral infections, and clinical studies of SARS-CoV-2 vaccines have been pursuing this therapeutic target.

**Management**

**Assessment and diagnosis.** In the context of the COVID-19 pandemic, the management of patients with eBC has become more complex, as SARS-CoV-2 infection can be symptomatic or asymptomatic. A summary of the recommendations discussed in the sections below is presented in Table 1.

The diagnosis of SARS-CoV-2 infection can be established on the basis of the reverse transcription-polymerase chain reaction (RT-PCR) test for symptomatic or asymptomatic patients exposed within 5-10 days to SARS-CoV-2–infected individuals. An RT-PCR should be performed, when available, 24-48 hours before the surgery and 14 days after self-isolation. Considering that RT-PCR has a false-negative rate of 20%-30%, < 10% of COVID-19–infected patients will inadvertently undergo surgery during the incubation period with this approach.

Serologic tests can be used for screening symptomatic patients after day 10 of symptoms as an alternative method to RT-PCR for COVID-19 diagnosis (gold standard). However, serologic tests alone are not recommended because they are less sensitive before 10 days of symptom onset and given the possibility of false positives.

Another practical approach is to assess eBC management in those cases with SARS-CoV-2 test results available (positive or negative) and a more controversial clinical scenario (Table 2). The risk of overall postoperative mortality is increased up to 6 weeks after SARS-CoV-2 infection. However, longer delays could negatively affect disease progression and patient outcome. This delay should be considered when deciding whether to postpone elective and nonurgent eBC surgeries in patients with preoperative positive SARS-CoV-2 diagnosis.

In addition, the decision to defer a surgical operation because of COVID-19 disease should be based on positive RT-PCR results (or antigen point-of-care [POC] tests when RT-PCR is unavailable) and clinical symptoms.
Impact of COVID-19 Disease in Early Breast Cancer Management

TABLE 1. Summary of Specialist Panel Recommendations

| Topic                        | Recommendation                                                                 |
|------------------------------|-------------------------------------------------------------------------------|
| Assessment and diagnostic   | RT-PCR is the gold standard for COVID-19 diagnosis. An RT-PCR should be       |
|                              | performed, when available, 24-48 hours before the surgery and 14 days after self- |
|                              | isolation.                                                                     |
|                              | Serologic tests can be used for screening symptomatic patients after day 10 of |
|                              | symptoms as an alternative method to RT-PCR for COVID-19 disease.             |
|                              | The POC antigen test is a viable approach when RT-PCR is unavailable. There   |
|                              | was no consensus regarding the utility of POC antibody tests.                 |
| Neoadjuvant therapy          | Neoadjuvant therapy is used to allow the delay of surgery. NET and NCT appear  |
|                              | to be safe choices to postpone nonurgent surgeries, and G-CSF can be used to   |
|                              | diminish neutropenia. Chemotherapy schedules may be modified to minimize      |
|                              | hospital visits.                                                               |
|                              | The panel recommends that the management of the axilla after neoadjuvant      |
|                              | therapy with positive SLN should be discussed on a case-by-case basis to       |
|                              | assess the possibility of omitting AD, especially after NET. AD is not        |
|                              | recommended if the SLN is negative at the time of surgery.                   |
| Radiotherapy                 | Hypofractionated schemes are used to minimize the number of visits to         |
|                              | radiotherapy centers. Radiotherapy could be omitted after surgery in > 65-year- |
|                              | old patients with < 2 cm HER2-positive tumors and negative axilla.           |
| Breast surgery               | The risk of contamination for less invasive surgeries, such as BCS, is low.    |
|                              | Whenever possible, more conservative surgeries should be indicated. The panel  |
|                              | suggests caution in recommending major surgery (such as mastectomies) during  |
|                              | the pandemic.                                                                  |
|                              | Contralateral prophylactic mastectomy is not recommended during the pandemic. |
|                              | BCS, or even unilateral mastectomy, should be considered as a replacement.    |
|                              | Immediate breast reconstruction should be evaluated on a case-by-case basis,   |
|                              | considering local sanitary conditions.                                        |
| COVID-19 vaccines and eBC    | Patients with eBC should take the COVID-19 vaccine as soon as it is available  |
|                              | and complete the vaccination scheme. If mammography is planned at the time of |
|                              | vaccination, it should be performed before vaccination, because of reports of  |
|                              | RNA vaccine-related axillary adenopathy 2-4 days after vaccination.           |

Abbreviations: AD, axillary dissection; BCS, breast conservative surgery; eBC, early breast cancer; G-CSF, granulocyte colony-stimulating factor; HER2, human epidermal growth factor receptor 2; NCT, neoadjuvant chemotherapy; NET, neoadjuvant endocrine therapy; POC, point-of-care; RT-PCR, reverse transcriptase polymerase chain reaction; SLN, sentinel lymph node.

testing results should not guide decision making, considering increased seroconversion of the population as vaccination progresses and other issues related to antibody tests discussed below.

Considerations on POC antigen and antibody testing as a replacement for RT-PCR. Antigen detection for the diagnosis of SARS-CoV-2 infection using POC tests provides a workable solution that could enable patients to self-isolate earlier and reduce the spread of infection, representing an option accessible to most outbreak areas compared with standard nucleic acid amplification tests, such as RT-PCR assays. However, the trade-off is a loss of sensitivity compared with nucleic acid amplification tests, particularly among asymptomatic patients. Trained professionals should carry out these tests.

The POC antigen test is a viable approach when RT-PCR is unavailable in the following scenarios:

- Patients presenting with 5- to 7-day onset of symptoms;
- Positive results need confirmation by RT-PCR assays (ideally);
- Outbreak areas and remote settings, where POC testing constitutes an alternative to RT-PCR.

On the other hand, serology tests have limited application diagnosis-wise, particularly in the acute phase, as most patients will develop an antibody response within 1-3 weeks after infection. Crucial windows of opportunity for clinical intervention and isolation measures might have already been missed.

There is also a possibility of cross-reaction with other pathogens, such as other human coronaviruses, increasing the odds for false positives. There was no consensus among the experts regarding the clinical utility of POC antibody tests. Some authors agreed that this technology could be considered in some situations, despite its limitations:

- determining the extent of infection in patients not diagnosed using RT-PCR;
- determining infection fatality rate, and
- supporting the development of vaccines.

Treatment

Neoadjuvant therapy to allow the delay of surgery. The clinical management guidelines for BC were recently updated in the COVID-19 era. Clinical cases eligible for neoadjuvant treatment are as follows:

- TNBC, HER2-positive, and luminal B tumors ≥ 2 cm and/or with positive axilla (≥ N1).
- Luminal A tumors stage T1-T2 and N0-N1 (neoadjuvant endocrine therapy [NET] may be recommended, especially in postmenopausal patients).
- Inflammatory and locally advanced BC (NET or neoadjuvant chemotherapy [NCT]).
Any type—to complete NCT that has already been initiated.

Specifically, for estrogen receptor–positive and HER2-negative patients, both the European Society for Medical Oncology and the American Cancer Society have stated that NET is an option to enable deferral of surgery by 6-12 months in clinical stage I or II BCs according to menopausal status. In addition, the Johns Hopkins Women’s Malignancies Program has developed a guideline for BC management during the COVID-19 pandemic on the basis of tumor biology and stage. Although constraints are often present in terms of resources, workforce, and hospital bed availability in the COVID-19 pandemic, causing a delay in procedures, both NET and NCT appear to be safe choices to postpone surgery in nonurgent indications of estrogen receptor–positive early-stage BC, also potentially contributing to a reduction in outpatient visits.

When NCT is proposed, there is a suggestion for using granulocyte colony-stimulating factor as support to diminish neutropenia. Regarding choices of chemotherapy regimens for early-stage BC, especially for TN, luminal B, and HER2-positive BCs, the recommendation is to follow the usual guidelines for these biologic subtypes. Chemotherapy schedules may be modified from weekly to every 3-week schedule, for example, to minimize hospital visits.

Managing axilla after neoadjuvant systemic therapy. As sentinel lymph node biopsy (SLNB) techniques become more widely practiced, invasive surgical methods for nodal staging such as axillary dissection (AD) are progressively de-escalated and restricted to specific scenarios. Surgeries have been a concern because of the risk of patient infection and human and resource restrictions during the COVID-19 pandemic. A multicenter retrospective study demonstrated that perioperative COVID-19–positive patients who underwent hip fracture surgeries had significantly higher postoperative morbidity and mortality.

According to the panel, AD is not recommended if SLNB is negative at surgery, even in the previously positive axilla. However, if the sentinel lymph node (SLN) is positive, the course of action should be discussed on a case-by-case basis, especially after NET.

| TABLE 2. SARS-CoV-2 Test Results in Specific eBC Clinical Scenarios | Clinical Scenario | Notes |
|---------------------------------------------------------------|------------------|-------|
| SARS-CoV-2 test                                              |                  |       |
| Positive RT-PCR                                              | eBC surgery planned | Defer elective eBC surgeries. There is no clinical recommendation to perform primary surgery in patients with eBC who test positive on RT-PCR for COVID-19 disease. The expert panel recommended deferring elective surgery for at least 30 days in asymptomatic patients. |
| RT-PCR results pending                                       | Patient with BC symptomatic for COVID-19 disease and positive epidemiology history for COVID-19 disease exposure | As vaccination progresses, situations where the patient has already received the full vaccination schedule will be common. Serologic tests may be positive for this patient profile (vaccine immunity), detecting vaccine antigenic targets or even a previous COVID-19 disease (natural immunity). This clinical scenario involving a symptomatic patient and negative RT-PCR will likely reflect diagnosis of an acute infectious disease diagnosis other than COVID-19 disease. Any patient with respiratory tract infections should have elective surgery postponed until symptom resolution. |
| Negative RT-PCR and positive serologic test                  | Patient with BC symptomatic for COVID-19 disease | Patients with urgent indications (eg, revision of an ischemic mastectomy flap and surgical evacuation of breast hematoma) should be submitted to surgery regardless of COVID-19 status, proceeding with all recommended precautions regarding PPE and patient logistics. |
| Negative RT-PCR                                               | Patient with BC symptomatic for COVID-19 disease and urgent surgery indication | RT-PCR test confirmation is crucial; therefore, the expert panel recommends postponing nonurgent hospital procedures for 10-14 days after symptom onset and 20 days for persistent symptoms. After that, the test is repeated. Patients with respiratory tract infections should have elective surgery postponed until symptom resolution. |
| Negative serologic test                                       | Patient with BC symptomatic for COVID-19 disease | Serologic testing should not be used to establish the presence or absence of COVID-19 disease or COVID-19 reinfection. Symptomatic patients should be diagnostically confirmed by RT-PCR. Patients with respiratory tract infections should have elective surgery postponed until symptom resolution. |

Abbreviations: BC, breast cancer; eBC, early breast cancer; PPE, personal protective equipment; RT-PCR, reverse transcription polymerase chain reaction.
Studies of adjuvant therapy in residual disease cases after NCT\textsuperscript{19,61} have demonstrated the importance of minimizing SLNB false-negative rates (FNRs).\textsuperscript{61} Failure in identifying residual disease in the axilla may alter clinical outcomes, as these patients would not be selected for additional treatment with trastuzumab emtansine, capecitabine, or olaparib. On the other hand, using chemotherapy regimens with lower odds of immunosuppression during the pandemic could decrease the complete pathologic response rate (pathologic complete response [pCR]) in these patients. An option to minimize the negative impact of modified chemotheraphy regimens over pCR in axilla-positive patients during the pandemic is to clip the lymph node before NCT. This approach reduces the FNR from 2\% to 8\%.\textsuperscript{62,63} Another alternative would be to perform SLNB with dual tracer. A meta-analysis of 1,921 patients showed an 11\% FNR with dual tracer and 4\% when three or more lymph nodes were harvested for biopsy.\textsuperscript{64} It is worth highlighting that assessing the breast sample is crucial to identify residual disease, as it is uncommon to simultaneously observe breast pCR and residual disease in the axilla.\textsuperscript{65}

With the increasing interest in omitting AD after NCT in the past few years, even in patients with residual disease on SLNB, a recent American study demonstrated that the use of isolated positive SLN after NCT has an upward trend after publication results of ACOSOG Z0011.\textsuperscript{66,67} The Z0011 study demonstrated excellent local and locoregional control with isolated sentinel lymph node biopsy but excluded patients who underwent oncologic units.\textsuperscript{76} The restrictions differ depending on the regional level of acuity of the pandemic, with a sudden reorganization of all clinical activities, demanded hospitals reallocate health care resources, with a sudden reorganization of all clinical activities, including oncologic units.\textsuperscript{76} The restrictions differ depending on the regional level of acuity of the pandemic and resources availability.

A retrospective review evaluated residual disease burden in positive SLN after NCT. It demonstrated an additional high disease burden, whether micrometastasis (59\%) or macrometastasis (63\%), possibly an indication for AD.\textsuperscript{68} Another analysis showed that the likelihood of non–SLN-centered metastasis at axillary lymph node dissection was high across all tumor subtypes.\textsuperscript{69} The core point is whether AD would play a role in residual lymph node disease cases or whether axillary radiation therapy could replace surgery in such cases. For instance, a retrospective study using data from the National Cancer Database (NCDB), with 1,617 women with N1 disease after NCT, compared patients who received AD associated with nodal radiotherapy with those who received only SLNB and radiotherapy, similar to the design of an ongoing randomized study of the ALLIANCE group (A11202)\textsuperscript{70} showing increased survival in women undergoing AD.\textsuperscript{71} However, in an exploratory analysis, the authors found that SLN was comparable with AD in luminal tumors with single metastases. The panel recommends caution in omitting AD in such cases.

On the other hand, after NET, pCR is generally not expected after systemic treatment.\textsuperscript{72} The question is whether these patients match the ACOSOG Z0011 study profile or otherwise. The data in this scenario are limited. A study using the NCDB and Dana-Farber/Brigham and Women’s Cancer Center database evaluated tumor burden after NET and the type of axillary surgery performed (SLNB or AD): more than 90\% of patients who had cNO axilla at initial presentation, in both cohorts, they had < 3 positive lymph nodes in the final pathology, with no difference in overall survival regardless of the type of axillary surgery.\textsuperscript{43} In another study, using the NCDB for stages 2 and 3, SLNB use after NET was similar to that for upfront surgery and, among those with pathological node-positive disease, the NET patients were less likely to undergo AD.\textsuperscript{73} In this scenario, the panel recommended a case-by-case assessment, with the possibility of omitting AD, especially in the initially clinically negative axilla. As NET and NCT become more common approaches during the COVID-19 pandemic, understanding nodal staging in these scenarios is even more relevant.

**Radiotherapy.** COVID-19 is a highly transmissible disease. Potential outbreaks within health care facilities such as radiotherapy services have been a concern since the pandemic, as inpatients and outpatients outside of COVID-19–restricted areas can get ill or further bring the virus to their communities. Thus, the panel recommended using hypofractionated schemes to minimize the number of visits to radiotherapy centers. Five-fraction schemes once a week (FAST trial)\textsuperscript{74} or daily fractions for one week (FAST forward trial)\textsuperscript{75} would be viable options for breast conservative surgery (BCS) in patients with negative axilla. A controversial topic is hypofractionation in chest wall after breast reconstruction. The panel believes that hypofractionation would be acceptable (eg, 15 fractions for three weeks)\textsuperscript{44} in this pandemic context. Elderly patients (\textgreater 65 years old) with \textlessthan; 2 cm HER2-negative tumors and negative axilla could have radiotherapy omitted after conservative surgery.\textsuperscript{45}

**Management of breast cancer surgeries in hospital restriction scenarios.** The COVID-19 pandemic has demanded hospitals reallocate health care resources, with a sudden reorganization of all clinical activities, including oncologic units.\textsuperscript{76} The restrictions differ depending on the regional level of acuity of the pandemic and resources availability.

**BCS and risk of infection by COVID-19 disease.** BCS is associated with lower rates of hospital stay and visits after surgery and hospitalization than mastectomy\textsuperscript{77}: a study with patients undergoing nipple-sparing mastectomy had total complication rates of 47\% and reoperations around 9\%.\textsuperscript{78} Regarding the use of oncplastic surgery, complication rates also tend to be higher than in BCS. In a study using the American College of Surgeons National Surgical Quality Improvement Program database, complications within 30 days were more significant in patients undergoing oncplastic surgery than BCS.
Another prospective cohort (TeaM Study) identified a reoperation rate of 2.8%. In a survey conducted during the pandemic among mastologists from the Brazilian Society of Mastology, 75% of surgeons would recommend partial reconstruction after BCS; however, 54% of those would contraindicate mammoplasty techniques during the pandemic. The panel recommends caution in recommending major surgery during the pandemic.

Although there are still limited data on this subject, it is possible to infer that the risk of contamination for less invasive surgeries, such as BCS, is low because of risks of procedure complications and lower surgery time. In addition, all precautions mentioned previously should also be taken for this surgical procedure.

**Elective surgeries that cannot be delayed.** Elective surgeries, by definition, can be postponed for up to 8 weeks. A few elective situations are considered essential and require planned or immediate medical assistance surgery-wise. Emergency or urgent surgeries might compromise patient survivorship if not performed. Examples of this type of surgery are a revision of an ischemic mastectomy flap, surgical evacuation of breast hematoma, drainage of breast abscess, and revascularization of an autologous tissue flap.

**Bilateral mastectomy.** Regarding patients with contralateral prophylactic mastectomy in unilateral BC indication, although there are still limited data on this subject, historically, these cases have a more extended hospital stay than to breast-conserving surgery or unilateral mastectomy and have more post-surgery visits and higher rates of hospitalization. This potential increase in patient exposure could lead to a greater risk of infection by COVID-19 disease. The expert panel suggested that a contralateral prophylactic mastectomy is not recommended during this period, and conservative breast surgery or even unilateral mastectomy should be carried out instead. The panel recommended that immediate breast reconstruction is evaluated on a case-by-case basis, according to the local conditions or resource availability because of the pandemics.

**COVID-19 vaccines and breast cancer.** According to the panel, patients with BC should receive the COVID-19 vaccine as soon as it becomes available since benefits are likely to outweigh the risks of adverse effects from SARS-CoV-2 vaccination. The National Comprehensive Cancer Network and the European Society for Medical Oncology recently reinforced this position. It is essential to point out that limited clinical data support COVID-19 vaccination in patients with cancer. A multicenter, observational, prospective study has shown that SARS-CoV-2–specific immunoglobulin G antibody response after natural infection does not differ in patients with cancer and healthy control patients. Two prospective observational studies have demonstrated that oncologic patients develop poor SARS-CoV-2 spike protein seroconversion after one dose of the BNT162b2 (Pfizer–BioNTech, Mainz, Germany) vaccine, but remarkably increased after the second dose, highlighting the importance of completing the vaccination scheme. However, it is uncertain whether long-term protection can be achieved in the oncologic population, as these studies rely on immunogenicity data alone, and real-world data on the long-term protection of vaccinated cancer patients against COVID-19 disease are limited. In the same vein, data from influenza vaccinations indicate the development of a protective immune response in patients with cancer, and, although potentially not the same level as the general population, it is generally safe. Again, there are long-term uncertainties, and the protection may vary depending on antineoplastic therapies, administration timing, disease stage, and comorbidities.

It is important to note that patients who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment should defer vaccination for at least 90 days as stated by the Centers for Disease Control and prevention recommendations. After the final dose is received, an individual is considered fully vaccinated after a minimum of 2 weeks. If the patient is asymptomatic and has not been in close contact with someone with SARS-CoV-2 infection in the past 14 days, the panel deemed it safe to conduct a surgical procedure. Patients with cancer and surgical patients, especially those undergoing chemotherapy or with chemotherapy planned within 8 weeks, are confirmed to be particularly at risk of infection and might have a negative outcome. A prospective cohort demonstrated that 30-day adjusted mortality was higher in patients with preoperative SARS-CoV-2 infection who had surgery 0-2 weeks, 3-4 weeks, and 5-6 weeks after the diagnosis of the infection (odds ratio [95% CI], 4.1 [3.3 to 4.8]; 3.9 [2.6 to 5.1], and 3.6 [2.0 to 5.2], respectively) compared with the mortality rate in patients without preoperative SARS-CoV-2 infection of 1.5% (95% CI, 1.4 to 1.5).

Vaccination reduces the odds of SARS-CoV-2 infection and negative outcomes of COVID-19 disease. The expert panel recommends that patients with eBC take the COVID-19 vaccine as soon as it is available to them and complete the vaccination scheme. Indeed, they are considered a priority group in national vaccination strategies. Although vaccinated individuals have a lower risk, the panel states that patients with eBC should keep social distancing, masks, and other protective measures. Table 3 summarizes the main vaccines approved worldwide on January 17, 2022.

Recently, an unexpectedly high incidence of axillary adenopathy findings after Moderna and Pfizer-BioNTech COVID-19 vaccines occurred. A solicited adverse event for patients receiving the Moderna vaccine was reported in 11.6% versus 5.0% for placebo after dose 1 and 16.0% versus 4.3% for placebo after dose 2. Adenopathy occurred in the arm and neck 2-4 days after vaccination with a median duration of 1-2 days. For those receiving the
Pfizer-BioNTech vaccine, resultant lymphadenopathy lasted for a mean of 10 days. However, in the Pfizer-BioNTech study, adenopathy was only reported as an unsolicited adverse event.46 A single-institution report found similar findings, and the authors are considering magnetic resonance imaging–detected isolated unilateral lymphadenopathy ipsilateral to the vaccination arm to be most likely COVID-19 vaccine–related if within 4 weeks of either dose.48 Five cases of COVID-19 vaccine–related axillary lymphadenopathy that mimicked metastasis in a vulnerable oncologic patient group have been described.93 Because of widescale vaccination, axillary lymphadenopathy because of COVID-19 vaccination is likely to be encountered in screening or diagnostic mammography. A recent retrospective study reported a vaccine axillary adenopathy incidence rate of 3% among women who underwent mammography after at least one vaccine dose. This study included data from 750 women, and most women with lymph nodes had received two vaccine doses (18 out 23 patients).94 Despite these findings, experts do not recommend postponing either vaccination or mammography but ideally performing mammography before vaccination.95 Few recommendations have been made to obtain supplementary information specific to the COVID-19 vaccine on the patient anamnesis, such as vaccination status date(s) of vaccination(s), type of vaccine, injection site (left or right arm), and any history of palpable axillary adenopathy. Radiologists and oncologists should be aware of this secondary effect of vaccination to avoid false-positive results and unnecessary changes in management, patient emotional stress, or biopsy.96,97

**What Is the Role of Postvaccine Antibody Quantification Tests in Patients With eBC?**

The current evidence supports that seroconversion rates among patients with cancer are similar to those without

---

**TABLE 3. COVID-19 Vaccine Candidates Approved**

| Manufacturer and Biotechnology of Cuba | Vaccine | Mechanism of Action | Patients With Cancer Enrolled? |
|--------------------------------------|---------|---------------------|-------------------------------|
| AstraZeneca/University of Oxford      | AZD-1222| Viral vector        | Only if malignancy with low potential risk for recurrence after curative treatment or metastasis (eg, indolent prostate cancer) at investigator discretion |
| Sinovac Biotech                      | CoronaVac| Inactivated virus  | No                            |
| Pfizer/BioNTech                      | BNT162b2| Lipid nanoparticle–encapsulated mRNA | No                            |
| Moderna/NIAID                        | mRNA-1273| Lipid nanoparticle–encapsulated mRNA | No                            |
| Gamaleya Research Institute          | Sputnik V| Viral vector        | No                            |
| Novavax                              | NVX-CoV2373| Recombinant protein| Only if basal cell carcinoma of the skin and cervical carcinoma in situ, at investigator discretion |
| Instituto Finlay de Vacunas          | Soberana 2| Recombinant protein| Only with stabilized disease and not undergoing chemotherapy/radiotherapy in the past 3 months |
| Beth Israel Deaconess Medical Center and Janssen | Ad26.COV2.S/JNJ-78436735| Inactivated virus | Only if squamous and basal cell carcinomas of the skin and cervical carcinoma in situ of the cervix or other malignancies with minimal risk of recurrence |
| CanSino Biologics                    | Convidecia/A d5-nCoV| Viral vector | Only if basal cell carcinoma of the skin and cervical carcinoma in situ |
| Anhui Zhifei Longcom                 | ZF2001/RBD-Dimer| Recombinant protein| Only if basal cell carcinoma |
| Beijing Institute of Biological Products (Sinopharm) | BBIBP-CorV (Vero Cells)| Inactivated virus | No |
| Wuhan Institute of Biological Products (Sinopharm) | BBIBP-CorV (Vero Cells)| Inactivated virus | No |
| Bharat Biotech                      | Covaxin/BBV152A, B, C| Inactivated virus | No |
| Chumakov Center                     | KoviVac/CovVac| Inactivated virus | Only if nonmelanoma skin cancer or cervical carcinoma in situ |

aData updated on January 17, 2022.
the disease, particularly in solid tumors like BC. Vaccine-wise, serologic tests can often be mis-interpreted as they might not distinguish between past infection and postvaccination immunologic response. Furthermore, serologic testing does not evaluate cellular immune response. When performed against nucleocapsid protein, these tests will not detect immune responses resulting from vaccination and are unsuitable for vaccine decision making. Most experts do not see a clinical application for these tests.

**DISCUSSION**

In conclusion, we have provided guidance on several topics regarding eBC management amid the COVID-19 pandemic to inform safer care practices for both patients and HCPs.

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Francisco Pimentel Cavalcante
Consulting or Advisory Role: Pfizer, Roche, MSD Oncology
Speakers’ Bureau: Roche, Pfizer, Gencell Pharma, Libbs
Travel, Accommodations, Expenses: Roche, Gencell Pharma
Carlos Eduardo dos Santos Ferreira
Speakers’ Bureau: Roche Diagnostica Brasil, Beckman Coulter, Abbott Diagnostics
Gilberto Amorim
Stock and Other Ownership Interests: Pfizer, AstraZeneca
Honorary: Roche, Novartis, Lilly, Sanofi/Aventis, Pfizer, MSD Oncology
Consulting or Advisory Role: Novartis, Roche, MSD Oncology
Travel, Accommodations, Expenses: Roche, Novartis
Luciana Landeiro
Consulting or Advisory Role: GlaxoSmithKline
Álvaro Pulchinielli Jr
Consulting or Advisory Role: Roche, Thermo Fisher Scientific, bioMerieux, BD Biosciences
Daniela Dornelles Rosa
Consulting or Advisory Role: Roche, Novartis, AstraZeneca, Lilly, GlaxoSmithKline, Sanofi, Libbs, Pfizer, Amgen, Zodiac Pharma
Speakers’ Bureau: Novartis, Lilly, Pfizer
Travel, Accommodations, Expenses: Roche

No other potential conflicts of interest were reported.
REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209-249, 2021
2. Siegel RL, Miller KD, Fuchs HE, et al: Cancer statistics, 2021. CA Cancer J Clin 71:7-33, 2021
3. Aguiar S, Baiocchi G, Duprat JP, et al: Value of preoperative testing for SARS-CoV-2 for elective surgeries in a cancer center during the peak of pandemic in Brazil. J Surg Oncol 122:1293-1295, 2020
4. Cavalcante FP, Novitá GG, Millen EC, et al: Management of early breast cancer during the COVID-19 pandemic in Brazil. Breast Cancer Res Treat 184:637-647, 2020
5. Papautsky EL, Hamilsh T: Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic. Breast Cancer Res Treat 184:249-254, 2020
6. Kaufman HW, Chen Z, Niles J, et al: Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. Jama Netw Open 3:ea2017267, 2020
7. Czajka ML, Pfeifer C: Breast cancer surgery, in StatPearls. Treasure Island, FL, StatPearls Publishing, 2020
8. Bartlett DL, Howe JR, Chang G, et al: Management of cancer surgery cases during the COVID-19 pandemic: Considerations. Ann Surg Oncol 27:1717-1720, 2020
9. American College of Surgeons: COVID-19 Antibody Testing. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html
10. Pryor A: SAGES and AEAs Recommendations Regarding Surgical Response to COVID-19 Crisis. 2020. https://www.sages.org/recommendations-surgical-response-covid-19
11. Hwang ES, Balch CM, Balch GC, et al: Surgical oncologists and the COVID-19 pandemic: Guiding cancer patients effectively through turbulence and change. Ann Surg Oncol 27:2600-2613, 2020
12. Ministério da Saúde, Brasil: Coronavírus Brasil, 2022. https://covid.saude.gov.br/
13. National Comprehensive Cancer Network: NCCN Guidelines: Breast Cancer, Version 1.2021—January 15, 2021. https://www.nccn.orgпрофессиональных/physician_gls/pdf/breast.pdf
14. Cardoso F, Kyriakides S, Ohno S, et al: Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194-1220, 2019
15. National Institute for Health and Care Excellence: COVID-19 Rapid Guideline: Arranging Planned Care in Hospitals and Diagnostic Services: NICE Guideline (NG179). https://www.nice.org.uk/guidance/ng179
16. Ribeiro R, Wainstein AJA, de Castro Ribeiro HS, et al: Perioperative cancer care in the context of limited resources during the COVID-19 pandemic: Brazilian Society of Surgical Oncology recommendations. Ann Surg Oncol 28:1289-1297, 2020
17. Dinnes J, Deeks JJ, Adriano A, et al: Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 3:CD013705, 2020
18. WHO: Antigen-Detection in the Diagnosis of SARS-CoV-2 Infection Using Rapid Immunodiassays: Interim Guidance, 2020. https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2-infection-using-rapid-immunodiassays.html
19. Centers for Disease Control and Prevention: Using Antibody Tests for COVID-19, 2020. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests.html
20. WHO: Advice on the Use of Point-of-Care Immunodiagnostic Tests for COVID-19: Scientific Brief, 2020. https://www.who.int/publications/i/item/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19-scientific-brief
21. Centers for Disease Control and Prevention: Sequence for Putting on Personal Protective Equipment (PPE). https://www.cdc.gov/hai/pdf/ppe/ppe-sequence.pdf
22. Centers for Disease Control and Prevention: Clinical Questions about COVID-19: Questions and Answers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html
23. Centers for Disease Control and Prevention: Interim Guidelines for COVID-19 Antibody Testing. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html
24. European Society for Medical Oncology: ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era: Breast Cancer. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era
25. Centers for Disease Control and Prevention: Interim U.S. Guidance for Risk Assessment and Work Restrictions for Healthcare Personnel with Potential Exposure to SARS-CoV-2. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assessment-hcp.html
26. National Comprehensive Cancer Network: Recommendations of the NCCN COVID-19 Vaccination Advisory Committee. https://www.nccn.org/covid-19
27. European Society for Medical Oncology: ESMO Statements for Vaccination Against COVID-19 in Patients With Cancer. https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination
28. Bitterman R, Eliaikim-Raz N, Vinograd I, et al: Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 2:CD008983, 2018
29. Centers for Disease Control and Prevention: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
30. Centers for Disease Control and Prevention: Updated Healthcare Infection Prevention and Control Recommendations in Response to COVID-19 Vaccination. https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-after-vaccination.html
31. Centers for Disease Control and Prevention: Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine. https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html
32. Simon SD, Bines J, Werutsky G, et al: Characteristics and prognosis of stage I-IIl breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast 44:113-119, 2019

ACKNOWLEDGMENT
All the authors contributed to writing the article and were approved to submit it for publication. In addition, the authors thank Dr Alexandre Ferreira Oliveira, Dr Gustavo Aguiar Campana, Dr Reitan Ribeiro, and Dr Ruffo Freitas Jr for their review and inputs. CoreBox Medical Communications provided medical writing assistance.
33. Dietz JR, Moran MS, Isakoff SJ, et al: Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. Breast Cancer Res Treat 181:487-497, 2020
34. Coates AS, Winer EP, Goldhirsch A; et al: Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533-1546, 2015
35. Marcus A, Gowen BG, Thompson TW, et al: Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 122:91-128, 2014
36. Cai G, Gao Y, Zeng S, et al: Immunological alternation in COVID-19 patients with cancer and its implications on mortality. Oncoimmunology 10:1854424, 2021
37. Hoffmann M, Kleine-Weber H, Schroeder S, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271-280.e8, 2020
38. Thervaraj I, Nguyen TH, Koutsakos M, et al: Breadth of concomitant immune responses prior to patient recovery: A case report of non-severe COVID-19. Nat Med 26:453-455, 2020
39. Han HJ, Nwagwu C, Anyim O, et al: COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol 90:1072-1074, 2021
40. Ferreira CE, Bonvehi PE, de la Torre JCG, et al: Algorithms for testing COVID-19 focused on use of RT-PCR and high-affinity serological testing: A consensus statement from a panel of Latin American experts. Int J Infect Dis 103:260-267, 2021
41. Mills GH: Respiratory complications of anaesthesia. Anaesthesia 73(suppl 1):25-33, 2018
42. Curigliano G, Cardoso MJ, Poortmans P, et al: Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. Breast 52:8-16, 2020
43. Kantor O, Wakeman M, Weiss A, et al: Axillary management after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. Ann Surg Oncol 28:1358-1367, 2021
44. Haviland JS, Owen JR, Dewar JA, et al: The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-Year follow-up results of two randomised controlled trials. Lancet Oncol 14:1086-1094, 2013
45. Kunkler I, Williams LJ, Jack JL, et al: PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): A randomised controlled trial. Lancet Oncol 16:266-273, 2015
46. Grimm L, Destounis S, Dogan B, et al: SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination, 2022. https://www.sbi-online.org/Portals/0/Position%20Statements/2022/SBI-recommendations-for-managing-axillary-adenopathy-post-COVID-vaccination_updatedFeb2022.pdf
47. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine. CDC, 2021. https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html
48. Edmondson CE, Zuckerman SP, Conant EF: Management of unilateral axillary lymphadenopathy detected on breast MRI in the era of coronavirus disease (COVID-19) vaccination. AJR Am J Roentgenol 217:831-834, 2021
49. Sethuraman N, Jeremiah SS, Ryo A: Interpreting diagnostic tests for SARS-CoV-2. JAMA 323:2249-2251, 2020
50. Mattoli IA, Hassan A, Oliveira ON, et al: On the challenges for the diagnosis of SARS-CoV-2 based on a review of current methodologies. ACS Sens 5:3655-3677, 2020
51. Li Y, Yao L, Li J, et al: Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol 92:903-908, 2020
52. COVIDSurg Collaborative, GlobalSurg Collaborative: Timing of surgery following SARS-CoV-2 infection: An international prospective cohort study. Anaesthesia 76:748-758, 2021
53. Finley C, Prashad A, Camuso N, et al: Guidance for management of cancer surgery during the COVID-19 pandemic. Can J Surg 63:S2-S4, 2020 (Suppl 1)
54. Pray IW: Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses—Wisconsin, September–October 2020. MMWR Morb Mortal Wkly Rep 69:1642-1647, 2021
55. Cheng MP, Yansouni CP, Basta NE, et al: Serodiagnosics for severe acute respiratory syndrome–related coronavirus-2. Ann Intern Med 173:450-460, 2020
56. Sheng JY, Santa-Maria CA, Mangini N, et al: Management of breast cancer during the COVID-19 pandemic: A stage- and subtype-specific approach. JCO Oncol Pract 16:665-674, 2020
57. Jatoi A, Ritter H, Dueck A, et al: A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (NCT0342399). Lung Cancer 68:234-239, 2020
58. Kayan B, Onoche E, Patil V, et al: The effects of COVID-19 on perioperative morbidity and mortality in patients with hip fractures. Bone Joint J 102-B:1136-1145, 2020
59. Masuda N, Lee SJ, Ohtani S, et al: Adjuvant cetuximab for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147-2159, 2017
60. von Minckwitz G, Huang CS, Mano MS, et al: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617-628, 2019
61. Tutt AN, Garber JE, Kaufman B, et al: Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384:2394-2405, 2021
62. Boughey JC, Suman VJ, Mittendorf EA, et al: Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:266-273, 2018
63. Caudle AS, Yang WT, Krishnamurthy S, et al: Selective evaluation of clipped nodes: Implementation of targeted axillary dissection. J Clin Oncol 34:1072-1078, 2016
64. Tutt AN, Garber JE, Kaufman B, et al: Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384:2394-2405, 2021
65. Boughey JC, Suman VJ, Mittendorf EA, et al: Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455-1461, 2013
66. Caudle AS, Yang WT, Krishnamurthy S, et al: Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection. J Clin Oncol 34:1072-1078, 2016
67. Tee SR, Devane LA, Evoy D, et al: Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-negative breast cancer. Br J Surg 105:1541-1552, 2018
68. Barron AU, Hoskin TL, Day CN, et al: Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast inhibitor. Cell 181:271-280.e8, 2020
69. Kantor O, Pepe C, Liederbach E, et al, for the ACOSOG Z0011 trial: Findings being applied to breast cancer patients undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat 181:487-497, 2020
70. Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy. 2021. https://clinicaltrials.gov2/c/show/NCT01901094
71. Almahariq MF, Levitin R, Quinn TJ, et al: Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy. Ann Surg Oncol 28:930-940, 2021
72. Hammond MEH, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/Clinical Practice Guidelines on the Use of Neoadjuvant Therapy for Early Breast Cancer. J Clin Oncol 36:210-234, 2018
73. Bi Z, Liu J, Chen P, et al: Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Breast Cancer 26:373-377, 2019
74. Brunt AM, Haviland J, Sydenham M, et al: FAST phase III RCT of radiotherapy hypofractionation for treatment of early breast cancer: 10-Year results (CRUKE/04/015). Int J Radiat Oncol Biol Phys 102:1603-1604, 2016
75. Brunt AM, Wheatley D, Yarnold J, et al: Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Fractionate Trial. Radiother Oncol 120:114-118, 2016
76. Freytag P, Gipponi M, Giacchino M, et al: Breast cancer surgery during the COVID-19 pandemic: An observational clinical study of the breast surgery clinic at Ospedale Policlinico San Martino—Genoa, Italy. In Vivo 34:1667-1673, 2020 (3 suppl)
77. Tuttle TM, Burke EE: Bilateral mastectomy: Doubling down on complications? Ann Surg Oncol 22:3407-3408, 2015
78. Valero MG, Muhsen S, Moo TA, et al: Increase in utilization of nipple-sparing mastectomy for breast cancer: Indications, complications, and oncologic outcomes. Ann Surg Oncol 27:344-351, 2020
79. Angarita FA, Acuna SA, Cordero E, et al: Thirty-day postoperative morbidity and mortality in elderly women with breast cancer: An analysis of the NSQIP database. Breast Cancer Res Treat 170:373-379, 2018
80. O’Connell RL, Baker E, Trickey A, et al: Current practice and short-term outcomes of therapeutic mammoplasty in the international TeaM multicentre prospective cohort study. Br J Surg 105:1778-1792, 2018
81. Cavalcante FP, Novita GG, Milen EC, et al: Breast reconstruction and coronavirus pandemic. J Plast Reconstr Aesthet Surg 74:644-710, 2021
82. Desai A, Ganor JF, Hegde A, et al: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 18:313-319, 2021
83. Corti C, Grimini E, Tarantini P, et al: Current perspectives: SARS-CoV-2 vaccines for cancer patients: A call to action. Eur J Cancer 148:316-327, 2021
84. Marra A, Generali DG, Zagami P, et al: LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study. Ann Oncol 31:S1206, 2020
85. Monin L, Laing AG, Muñoz-Ruiz M, et al: Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study. Lancet 22:765-778, 2021
86. Goshen-Lago T, Waldhorn I, Holland R, et al: Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol 7:1507-1513, 2021
87. Miraglia JL, Abdala E, Hoff PM, et al: Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS One 6:e27214, 2011
88. Brydak LB, Guzy J, Starzyk J, et al: Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 9:65-68, 2001
89. Ward EM, Flowers CR, Gansler T, et al: The importance of immunization in cancer prevention, treatment, and survivorship. CA Cancer J Clin 67:398-410, 2017
90. Loulergue P, Alexandre J, Iurisci I, et al: Low immunogenicity of seasonal trivalent inactivated influenza vaccine among patients receiving docetaxel for a solid tumour: Results of a prospective pilot study. Br J Cancer 104:1670-1674, 2011
91. Spolverato G, Capelli G, Restivo A, et al: The management of surgical patients during the coronavirus disease 2019 (COVID-19) pandemic. Surgery 168:4-10, 2020
92. Ministério da Saúde (Brasil): Plano Nacional de Operacionalização da Vacina contra a Covid-19—4 a Edição. https://www.gov.br/saude/pt-br/Coronavirus/vacinas/plano-nacional-de-operacionalizacao-da-vacina-contra-a-covid-19
93. Özdemir C, Krystosek LA, Church AL, et al: Lymphadenopathy in COVID-19 vaccine recipients: Diagnostic dilemma in oncologic patients. Radiology 300:E296-E300, 2021
94. Robinson KA, Maimone S, Gococo- Benore DA, et al: Incidence of axillary adenopathy in breast imaging after COVID-19 vaccination. JAMA Oncol 7:1395-1397, 2021
95. Ministry of Health (Brazil): Informações atualizadas sobre vacinação contra COVID-19 e Mamografia. https://www.gov.br/saude/pt-br/Coronavirus/vacinas/plano-nacional-de-operacionalizacao-da-vacina-contra-a-covid-19
96. ¨Oz ¨utemiz C, Krystosek LA, Church AL, et al: Lymphadenopathy in COVID-19 vaccine recipients: Diagnostic dilemma in oncologic patients. Radiology 300:E296-E300, 2021
97. Thakkar A, Pradhan K, Jindal S, et al: Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy. Nat Cancer 2:392-399, 2021